Astegolimab
As of the edition of 20 October 2026, Astegolimab is an antibody: in active development; acts on IL1RAP and IL1RL1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2027
- Kind
- Antibody
- Registered trials
- 9, 0 stopped early
- Disease areas
- Lungs and airways; Immune system; Inherited and neonatal; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 5 | 5 | 0 | 0 |
| Phase 3 | 2 | 0 | 2 | 0 |
| All trials | 9 |